FDA Standard Review vs Priority Review: Criteria, Timelines, and Differences
Standard review gives FDA 10 months from filing to act on an NDA or BLA, while priority review shortens that to 6 months. Priority review is granted to drugs that demonstrate significant improvement in the treatment, diagnosis, or prevention of a serious condition compared to available therapies. Both carry a 90% on-time performance goal under PDUFA VII, and the user fee is identical.
Key Takeaways
Key Takeaways
- Priority review shortens the FDA review period from 10 months to 6 months but does not change the approval standard — the same evidence of safety and efficacy is required.
- Eligibility requires a significant improvement in treatment, diagnosis, or prevention of a serious condition compared to available therapies.
- The PDUFA user fee is identical for both standard and priority review; the only additional cost arises from Priority Review Voucher (PRV) redemption.
- Priority review can be granted on its own or alongside other expedited programs, but FDA does not apply it automatically to every serious-condition application.
- Standard review and priority review are the two review classifications FDA assigns to every original New Drug Application (NDA) and Biologics License Application (BLA) upon filing. This classification determines the PDUFA goal date and the pace at which FDA allocates review resources. Understanding the distinction is essential for regulatory strategy, launch planning, and investor communications. For full context on how review timelines fit within the broader FDA drug approval timeline, see our dedicated guide.
- Priority review is not a separate pathway or approval standard. The evidentiary requirements for approval are identical regardless of review classification. Priority review simply compresses the timeline by committing FDA to complete its review 4 months faster. The drug must still meet the same statutory standard of substantial evidence of effectiveness and adequate safety (21 USC 355(d) for NDAs; 42 USC 262 for BLAs).
- In this guide, you will learn:
- The precise criteria FDA uses to grant priority review
- How to request priority review and what the review process looks like
- Head-to-head comparison of standard vs priority review across all key dimensions
- The Priority Review Voucher (PRV) program and its implications
- Historical approval rates and on-time performance for both classifications
- How priority review interacts with other expedited programs
- Related guides:
- PDUFA dates 2026
- FDA review clock explained
- FDA approval process step by step
- FDA user fee programs guide
- Fast Track designation
- Breakthrough Therapy designation
- ---
Standard Review: The Default Classification
Definition and Legal Basis
Standard review is the default review classification for all original NDAs and BLAs. Under PDUFA VII (FD&C Act Sections 735-736, as reauthorized by FDORA, Pub. L. 117-328), FDA commits to reviewing standard applications within 10 months of the filing date.
The 10-month clock begins on the day FDA issues a filing letter (typically Day 74 after submission), not on the day the sponsor submits the application.
Standard Review Timeline
| Milestone | Timing | Details |
|---|---|---|
| Application submission | Day 0 | Sponsor submits NDA/BLA via ESG in eCTD format |
| User fee payment | Within 20 days | PDUFA fee must be paid (FD&C Act 736(a)) |
| Filing review period | Days 1-60 | FDA assesses completeness (21 CFR 314.101) |
| Filing letter / RTF | ~Day 74 | FDA communicates filing decision |
| PDUFA clock starts | Filing date | 10-month review period begins |
| Mid-cycle communication | ~Month 5-6 | FDA provides review status update |
| Labeling discussions | Months 3-8 | Draft label negotiations |
| GCP/GMP inspections | Months 3-8 | Clinical site and manufacturing facility inspections |
| Advisory Committee | If convened | Independent expert panel (not required for all applications) |
| PDUFA date action | Month 10 | Approval, CRL, or extension |
| Total time (submission to action) | ~12 months | Including 60-day filing review |
When Standard Review Applies
Standard review is assigned when the drug does not qualify for priority review. This includes drugs that:
- Offer therapeutic benefit similar to existing approved therapies
- Address conditions where satisfactory treatments already exist
- Represent incremental improvements in formulation, delivery, or convenience without a significant clinical advantage
- Do not meet the "significant improvement" threshold for priority review
“Note: Standard review does not imply the drug is less important or less likely to be approved. Many transformative therapies have received standard review because effective treatments already existed in the therapeutic area.
Priority Review: Criteria and Process
Definition and Legal Basis
Priority review is a review classification that shortens the FDA review period from 10 months to 6 months. It was established under the 1992 PDUFA legislation and is codified in FDA's procedures for review classification.
FDA Guidance, "Priority Review" (February 2018), defines the eligibility criteria:
“A priority review designation directs overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.
Eligibility Criteria
To qualify for priority review, the application must demonstrate:
1. Serious Condition
The drug must be intended to treat, diagnose, or prevent a serious condition. FDA defines "serious" broadly to include conditions that have substantial impact on day-to-day functioning or are life-threatening. Examples include cancer, heart disease, HIV/AIDS, Alzheimer's disease, epilepsy, depression, and diabetes. The FDA Guidance on Expedited Programs (2014) provides the full framework.
2. Significant Improvement
The drug must represent a significant improvement over available therapy in one or more of these dimensions:
| Improvement Type | Examples |
|---|---|
| Effectiveness | Superior efficacy in head-to-head trial, efficacy in non-responders |
| Safety | Elimination of a significant adverse reaction, reduced drug interactions |
| Diagnosis | Earlier or more accurate detection of serious condition |
| Patient impact | Substantially improved convenience leading to better adherence |
| Population | Efficacy in subpopulation where no treatment exists |
"Significant improvement" is evaluated relative to currently available therapies at the time of the priority review decision, not at the time of clinical trial initiation.
How to Request Priority Review
| Step | Timing | Details |
|---|---|---|
| 1. Include request in application | At NDA/BLA submission | Submit priority review request with supporting rationale in Module 1 |
| 2. FDA evaluates | During 60-day filing review | Review division assesses against criteria |
| 3. Classification decision | Day ~60-74 | FDA informs sponsor in filing communication |
| 4. Appeal (if denied) | After filing letter | Sponsor may provide additional rationale |
The request should include:
- Comprehensive comparison to available therapies
- Clinical data supporting the claimed improvement
- Applicable unmet medical need documentation
- Reference to relevant FDA guidance
“Important: There is no separate form or fee for requesting priority review. The request is included as part of the NDA/BLA submission, typically in a cover letter or dedicated section of Module 1.
Priority Review Timeline
| Milestone | Timing | Difference from Standard |
|---|---|---|
| Application submission | Day 0 | Same |
| Filing review | Days 1-60 | Same |
| Filing letter / PDUFA date set | ~Day 74 | Same filing process |
| PDUFA clock starts | Filing date | Same |
| Mid-cycle communication | ~Month 3-4 | Earlier than standard |
| Inspections | Months 2-5 | Compressed schedule |
| Advisory Committee | If convened | Same process |
| PDUFA date action | Month 6 | 4 months earlier than standard |
| Total time (submission to action) | ~8 months | ~4 months shorter |
Head-to-Head Comparison
| Dimension | Standard Review | Priority Review |
|---|---|---|
| Review period | 10 months from filing | 6 months from filing |
| Total time (including filing) | ~12 months | ~8 months |
| Performance goal | 90% on time | 90% on time |
| User fee (FY 2026) | $4,682,003 | $4,682,003 (identical) |
| Approval standard | Substantial evidence | Substantial evidence (identical) |
| Eligibility | All NDAs/BLAs (default) | Significant improvement for serious condition |
| Request process | Automatic | Must be requested at submission |
| Advisory Committee | At FDA discretion | At FDA discretion (same) |
| Inspection requirements | Same GCP/GMP standards | Same standards, compressed schedule |
| Post-marketing requirements | Based on product profile | Based on product profile (same) |
| Labeling process | Same USPI/PI process | Same process, compressed timeline |
| Can be combined with | N/A | Fast Track, Breakthrough, Accelerated Approval |
Approval Rate Comparison
Historical data from FDA annual reports shows comparable approval rates:
| Metric | Standard Review | Priority Review |
|---|---|---|
| Approval rate (first cycle) | ~82-88% | ~85-92% |
| On-time action rate | 91-95% | 93-96% |
| Early action rate | ~35-45% | ~45-55% |
| Advisory Committee frequency | ~15-25% | ~20-30% |
“Key Point: The slightly higher approval rate for priority review applications likely reflects selection bias: drugs with stronger clinical profiles are more likely to receive priority review designation and more likely to be approved. Priority review itself does not make approval more likely.
Priority Review Voucher (PRV) Program
The Priority Review Voucher program creates a transferable voucher granting priority review to a future application. The PRV program operates under three separate statutory authorities:
Types of PRV Programs
| Program | Statutory Authority | Eligibility |
|---|---|---|
| Rare Pediatric Disease PRV | FD&C Act Section 529 (added by FDASIA 2012) | Approval of drug for rare pediatric disease |
| Tropical Disease PRV | FD&C Act Section 524 (added by FDA Amendments Act 2007) | Approval of drug for qualifying tropical disease |
| Medical Countermeasure PRV | FD&C Act Section 565A (added by 21st Century Cures Act 2016) | Approval of material threat medical countermeasure |
How PRVs Work
- A sponsor receives FDA approval for a qualifying product (rare pediatric disease, tropical disease, or medical countermeasure)
- FDA issues a Priority Review Voucher along with the approval
- The voucher holder can:
- Redeem the PRV on a future NDA or BLA to receive 6-month priority review (regardless of whether the drug would otherwise qualify)
- Transfer/sell the PRV to another company
PRV vs Standard Priority Review
| Feature | Priority Review (by qualification) | Priority Review (by PRV redemption) |
|---|---|---|
| Review timeline | 6 months | 6 months |
| Drug must qualify | Yes (significant improvement) | No (voucher grants it regardless) |
| Additional fee | None | A separate PRV user fee applies when a voucher is redeemed |
| Total cost | Standard PDUFA fee | Standard PDUFA fee plus the applicable PRV fee and any private transfer cost |
Priority Review and Other Expedited Programs
Priority review can be combined with FDA's other three expedited programs. Understanding these interactions is important for regulatory strategy.
Program Overlap Matrix
| Program Combination | Possible? | Combined Effect |
|---|---|---|
| Priority Review + Fast Track | Yes | 6-month review + rolling submission |
| Priority Review + Breakthrough Therapy | Yes | 6-month review + intensive FDA engagement |
| Priority Review + Accelerated Approval | Yes | 6-month review + surrogate endpoint approval |
| Priority Review + Fast Track + Breakthrough | Yes | All benefits combined |
| All four programs | Yes | Maximum expedited pathway |
How Each Program Differs
| Program | What It Does | When Granted | FD&C Act Section |
|---|---|---|---|
| Fast Track | Rolling review, more frequent meetings | Any time during development | 506(b) |
| Breakthrough | Intensive FDA guidance, rolling review | After preliminary clinical evidence | 506(a) |
| Accelerated Approval | Approval on surrogate endpoint | Before Phase 3 endpoint selection | 506(c) / 21 CFR 314 Subpart H |
| Priority Review | 6-month review period | At NDA/BLA submission | PDUFA VII |
“Strategic Consideration: Breakthrough Therapy designation and priority review are separate regulatory decisions. A sponsor should request and justify priority review even if another expedited program already applies.
Supplemental Applications: Standard vs Priority
Priority review applies not only to original NDAs/BLAs but also to efficacy supplements.
Supplement Review Timelines Under PDUFA VII
| Supplement Type | Standard Review | Priority Review |
|---|---|---|
| Original efficacy supplement | 10 months | 6 months |
| Class 1 resubmission (minor) | 2 months | 2 months |
| Class 2 resubmission (major) | 6 months | 6 months |
| Manufacturing supplement (prior approval) | 4 months | N/A |
| Labeling supplement | 4 months | N/A |
An efficacy supplement seeking a new indication for an already-approved drug can receive priority review if the new indication meets the same "significant improvement for a serious condition" criteria.
How to Determine if Your Drug Qualifies
Self-Assessment Framework
Evaluate your drug against these criteria before requesting priority review:
Step 1: Is the condition "serious"?
- Does it have substantial impact on day-to-day functioning?
- Is it life-threatening or potentially life-threatening?
- Is the condition listed in FDA's guidance on serious conditions?
Step 2: Is the improvement "significant"?
- Does head-to-head or historical comparison show meaningful improvement?
- Is the improvement in effectiveness, safety, or patient impact?
- Would a reasonable clinician consider this a meaningful advance?
Step 3: What are the current treatment options?
- Are there approved therapies for this condition?
- How does your drug compare to the standard of care?
- Is there an unmet medical need?
Common Reasons for Priority Review Denial
| Reason | Example |
|---|---|
| Condition not considered "serious" | Cosmetic conditions, mild allergies |
| Improvement not "significant" | Same efficacy with slightly different side effect profile |
| Adequate therapies exist | New statin for hypercholesterolemia without clear advantage |
| Insufficient comparative data | No head-to-head trial, inadequate historical comparison |
| Convenience-only improvement | New formulation without clinical benefit (typically) |
Priority review means FDA completes its review in 6 months instead of 10 months. It does not change the approval standard, the type of data required, or the likelihood of approval. A drug still must meet the same evidentiary bar for safety and efficacy.
Key Regulatory References
| Reference | Citation |
|---|---|
| Priority Review Guidance | FDA, "Priority Review," February 2018 |
| Expedited Programs Guidance | FDA, "Expedited Programs for Serious Conditions," 2014 |
| PDUFA VII Commitment Letter | FDA, September 2022 |
| PDUFA VII Reauthorization | FDORA, Pub. L. 117-328, Division FF, December 2022 |
| NDA Filing and Review | 21 CFR 314.101, 314.110 |
| BLA Filing and Review | 21 CFR 601.2 |
| Rare Pediatric Disease PRV | FD&C Act Section 529 |
| Tropical Disease PRV | FD&C Act Section 524 |
| Medical Countermeasure PRV | FD&C Act Section 565A |
| Approval Standard (NDA) | 21 USC 355(d) |
| Approval Standard (BLA) | 42 USC 262 |
References
Sources
- Priority Review | FDA
- Expedited Programs for Serious Conditions: Drugs and Biologics | FDA
- Prescription Drug User Fee Amendments | FDA
- 21 CFR 314.101 | eCFR
- 21 CFR 314.110 | eCFR
- 21 CFR 601.2 | eCFR
- 21 U.S.C. 355 | Legal Information Institute
- 42 U.S.C. 262 | Legal Information Institute
- 21 U.S.C. 360n | Legal Information Institute
- 21 U.S.C. 360ff | Legal Information Institute
- 21 U.S.C. 360bbb-4a | Legal Information Institute